Loading patent…
AssigneeGliatech, Inc.
InventorsDikla Roufa, Adrian Harel, Robert C.A. Frederickson, George T. Coker III
Estimating the term…
The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that the effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer. Thus the present invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used. In a more preferred embodiment, the average molecular weight is about 40,000 to 500,000 Daltons. The present invention provides compositions and methods to inhibit fibrosis and scarring associated with surgery. The invention further provides compositions and methods to inhibit glial cell invasion, detrimental bone growth and neurite outgrowth. In a preferred embodiment, the inhibitory compositions further comprise an adhesive protein.
A composition comprising an amount of an anionic polymer effective to inhibit cell invasion or fibrosis, and a pharmaceutically acceptable carrier, in which the carrier is selected from the group consisting of a solid carrier or a semi-solid carrier.
A composition comprising an amount of dextran sulfate effective to inhibit cell invasion or fibrosis, in which the sulfur content of the dextran sulfate is greater than about 10% by weight, and a pharmaceutically acceptable carrier in which the carrier is selected from the group consisting of a solid carrier and a semi-solid carrier.
A composition comprising an amount of a cross-linked anionic polymer effective to inhibit cell invasion or fibrosis, and a pharmaceutically acceptable solution, which cross-linked anionic polymer demonstrates greater viscosity in solution than the same amount of non-cross-linked anionic polymer in the same volume of solution.
A composition comprising an amount of cross-linked dextran sulfate effective to inhibit cell invasion or fibrosis, in which the sulfur content of the dextran sulfate is greater than about 10% by weight, and a pharmaceutically acceptable solution, which cross-linked dextran sulfate demonstrates greater viscosity in solution than the same amount of non-cross-linked dextran sulfate in the same volume of solution.
An inhibitory-adhesive composition comprising:
An inhibitory-adhesive composition comprising:
A method for inhibiting fibrosis, granulation or scar formation of a lesion comprising administering a therapeutically effective amount of a composition comprising an anionic polymer to the site of the lesion.
A method for inhibiting fibrosis, granulation or scar formation of a lesion comprising administering a therapeutically effective amount of a composition comprising dextran sulfate to the site of the lesion, in which the sulfur content of the dextran sulfate is greater than about 10%.
A method for inhibiting fibrosis, granulation or scarring of a lesion comprising the following steps:
A method for inhibiting fibrosis, granulation or scarring of a lesion comprising the following steps:
A method of inhibiting fibrosis in a subject following laminectomy, comprising administering a composition comprising a therapeutically effective amount of an anionic polymer to a laminectomy site in an animal.
A method of inhibiting fibrosis in a subject following laminectomy, comprising administering a composition comprising a therapeutically effective amount of dextran sulfate, in which the sulfur content of the dextran sulfate is greater than about 10%, to a laminectomy site in an animal.
A method for inhibiting neurite outgrowth comprising administering to a site where inhibition of neurite outgrowth is desired a composition comprising a therapeutically effective amount of an anionic polymer, in which the anionic polymer is selected from the group consisting of dextran sulfate, pentosan polysulfate, alginate and an anionic polymer which comprises an acid sulfate in which the sulfur content is greater than about 10%.
A method for treatment of gliomas, tumors of nerve tissue, neuroma, or overproduction of nerve-growth promoting factors in an animal comprising administering to a site where treatment is desired a composition comprising a therapeutically effective amount of an anionic polymer, in which the anionic polymer is selected from the group consisting of dextran sulfate, pentosan polysulfate, alginate and an anionic polymer which comprises an acid sulfate in which the sulfur contents is greater than about 10%.
A method of inhibiting neurite outgrowth comprising the following steps:
A method of inhibiting neurite outgrowth comprising the following steps:
A method of inhibiting bone growth in an animal comprising administering a therapeutically effective amount of an anionic polymer to a site where inhibition of bone growth is desired.
A method of inhibiting bone growth in an animal comprising administering a therapeutically effective amount of dextran sulfate, in which the sulfur content of the dextran sulfate is greater than about 10%, to a site where inhibition of bone growth is desired.
A method of inhibiting bone growth in a subject comprising the following steps:
A method of inhibiting bone growth comprising the following steps:
A method of inhibiting glial cell invasion comprising administering to a site where inhibition of glial cell invasion is desired a composition comprising a therapeutically effective amount of an anionic polymer selected from the group consisting of dextran sulfate, pentosan polysulfate, alginate and an anionic polymer which comprises an acid sulfate in which sulfur content is greater than about 10%.
A method of inhibiting glial cell invasion comprising the following steps:
A method of inhibiting glial cell invasion comprising the following steps:
A method of inhibiting neuroma formation comprising the following steps:
A method of inhibiting neuroma formation comprising the following steps:
A method of inhibiting fibrosis around an implant in an animal comprising applying a composition comprising an effective amount of an anionic polymer to an implant;
A method of inhibiting fibrosis around an implant in an animal comprising applying a composition comprising an effective amount of dextran sulfate to an implant, in which the sulfur content of the dextran sulfate is greater than about 10%;
Dependencies are inferred from the claim text.